Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

Overview of attention for article published in Clinical Cancer Research, August 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#21 of 13,309)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 56 news outlets
twitter: 14 X users

patent: 1 patent

Citations

dimensions_citation: 197 Dimensions

Readers on

mendeley: 129 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 16 X posts from 14 X users, with an upper bound of 40,827 followers.

Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials https://t.co/j5u9yP4Ap3. 2PR,1SD of 44mo. Interesting. What about the edito saying it is "well tolerated"?? 1 grade 5 CRS (toxic death) on

09 Oct 2020

Reply Repost Favourite

Phase 1 Study: CAR-GPC3 T cells for advanced hepatocellular carcinoma. https://t.co/VwTTaetOwj https://t.co/sLyLETvgJJ

12 Aug 2020

Reply Repost Favourite

RT @nanudasmd: Exciting to see CAR-T cells enter the arena for GI malignancies (HCC)...though toxicity appears to be a significant issue, s…

11 Aug 2020

Reply Repost Favourite

RT @nanudasmd: Exciting to see CAR-T cells enter the arena for GI malignancies (HCC)...though toxicity appears to be a significant issue, s…

10 Aug 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.